Talquetamab Step-Up Dosing Strategies and CRS Monitoring
Panelist discusses how talquetamab’s step-up dosing strategy aims to mitigate cytokine release syndrome, a common immunologic toxicity. The reported grade 1 CRS with altered taste and dry mouth represents a mild manifestation compared with the MonumenTAL-1 trial, where the initial SUD schedule showed varying CRS rates. Real-world evidence has largely validated trial findings, though alternative SUD approaches may offer different risk-benefit profiles. The optimal SUD strategy continues to evolve as clinical experience expands, balancing efficacy with tolerability.
Video content above is prompted by the following:
- Following the second step-up dose, the patient experiences grade 1 cytokine release syndrome (CRS), reporting altered taste and dry mouth.
- Please briefly discuss CRS, step-up dosing (SUD), and initial challenges when using talquetamab in this setting.
- How do these findings compare with real-world evidence?
- How do alternative SUD strategies impact CRS outcomes from MonumenTAL-1?
Lisaftoclax Plus Pd Demonstrates Strong Response and Safety in RRMM
December 10th 2024Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.
Read More
